IFNA1 and nonpapillary renal cell carcinoma: Third, our discovery of an interferon signature in ccRCC offers opportunities for immunotherapies and IFN-based therapeutics, as the ccRCC interferon signature includes several genes involved in antigen presentation and immune cell recruitment (e.g. HLA genes, B2M, several chemokine genes, Table S4).